2 Results Found

Advanced Search

Select all

Results per page

Select all

Article

1,228 Views

18 Pages

VVX001 Induces preS-Specific Antibodies Reacting to Common HBV Genotypes in Hepatitis B Virus (HBV) Carrier Mice

Inna Tulaeva,
Maryline Bourgine,
Carolin Cornelius-Nikl,
Alexander Karaulov,
Rainer Henning,
Marie-Louise Michel and
Rudolf Valenta

Vaccines2025, 13(8), 854;https://doi.org/10.3390/vaccines13080854

-

12 August 2025

Background: Chronic hepatitis B (CHB) remains being a major public health threat, and currently existing CHB therapies have limited efficacy and side effects. We have recently developed a vaccine termed VVX001 based on a recombinant fusion protein co...

Full Article

Article

2 Citations

4,250 Views

19 Pages

The PreS-Based Recombinant Vaccine VVX001 Induces Hepatitis B Virus Neutralizing Antibodies in a Low-Responder to HBsAg-Based HBV Vaccines

Inna Tulaeva,
Felix Lehmann,
Nora Goldmann,
Alexandra Dubovets,
Daria Trifonova,
Mikhail Tulaev,
Carolin Cornelius,
Milena Weber,
Margarete Focke-Tejkl and
Rudolf Valenta
+ 5 authors

Vaccines2024, 12(10), 1123;https://doi.org/10.3390/vaccines12101123

-

30 September 2024

Background: Approximately 10–20% of subjects vaccinated with HBsAg-based hepatitis B virus (HBV) vaccines are non-responders. BM32 is a recombinant grass pollen allergy vaccine containing the HBV-derived preS surface antigen as an immunological...

Full Article